Back to search results

Home-Based Exercise for Bladder and Urothelial Cancer

This study, called the "Get Moving Trial," is looking at whether a personalized exercise program done at home can help improve physical function in people with bladder cancer or upper tract urothelial cancer (cancer in the kidney or ureter) before surgery. You would either receive educational materials and use a Fitbit app, or you would follow a personalized exercise program using the ExerciseRx app and also use a Fitbit app. The goal is to see if this exercise program can help you be more active and have better physical function before and after your surgery. The study aims to enroll 128 participants and is currently unclear about its recruitment status.

Study design
This is an interventional study where participants are randomly assigned to one of two groups. It plans to enroll 128 participants.
What's involved
You would be on the study for about 4-7 months, including at least 4 weeks of intervention before surgery and 90 days of follow-up after surgery. This involves using apps and potentially following an exercise program.
Compensation
Not stated in the trial record.
Follow-up
Participants are followed for 90 days after their surgery.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06040762

A Home-Based Prehabilitation Exercise Intervention for Improving Physical Function in Patients With Bladder Cancer and Upper Tract Urothelial Cancer, Get Moving Trial

Recruiting
NAAges 18+InterventionalSupportive care
University of Washington
~128 participants
Updated 2026-09-10 on ClinicalTrials.gov
What's tested:Best PracticeExercise InterventionApp-Based InterventionInterviewWearable Activity TrackerPhysical Performance Testing

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Trial recruitment
Measured over At enrollment
+4 more outcomes measured

Conditions

Bladder Cancer
Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Renal Pelvis and Ureter Urothelial Carcinoma

Explore related trials

Bladder CarcinomaRenal Pelvis and Ureter Urothelial Carcinoma

NCT06040762

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Fred Hutch/University of Washington Cancer Consortium

    Seattle, Washingtonstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Sarah Psutka · PRINCIPAL_INVESTIGATOR · Fred Hutch/University of Washington Cancer Consortium

Who to contact

Get Moving Research Coordinator
[email protected]
206-210-4040
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

18 years of age or older
English-speaking
Planned treatment with radical cystectomy or radical nephroureterectomy/ureterectomy with or without preceding systemic therapy as indicated by the patient's surgeon with enough time to complete a minimum of 4 weeks of exercises before surgery if enrolled in the (P)REHAB arm
Willing and able to participate in trial activities

Exclusion

Cognitive/mental impairment that will preclude ability to participate in routine exercise activities. Significant cognitive or memory impairment or baseline dementia that would preclude a patient's ability to follow instructions or reproduce exercises
Immobility, inability/unwillingness to perform personalized exercise program. Inability to perform exercises safely from seated or standing position at home or recent falls or high fall risk. Neurologic or orthopedic condition(s) that restricts participation in unsupervised home exercises, such as prior stroke with neurologic impairment, weight-bearing precautions, or unwillingness to participate in exercises
Participants who have nonmuscle-invasive urothelial cancer of the bladder/upper tract anticipating undergoing organ-preserving treatments, or radiographic evidence of metastatic disease involving other organs including brain metastases.
Patients with predominant histology other than urothelial carcinoma of the bladder or upper tracts (e.g. metastasis from another cancer) who would not otherwise be considered candidates for standard definitive or consolidative surgeries (radical cystectomy, ureterectomy, radical nephroureterectomy) with/without treatment with preoperative/neoadjuvant systemic therapy.
Uncontrolled or concurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
Pregnant women are excluded from this study
Inability to understand or read English
Lack of access or lack of sufficient facility to use an Android or iOS smart device with the minimum criteria for using ExerciseRx
Not receiving surgery at UWMC
Participation in a clinical trial that does not permit enrollment in the Get Moving trial

What this trial measures

  • Trial recruitmentAt enrollment

    Trial recruitment (proportion enrolled versus eligible, reason for not enrolling) will be described via qualitative report.

  • Trial retentionThrough study completion, on average 4-7 months

    Trial retention (proportion retained versus all enrolled, reason for not completing) will be described via qualitative report. Successful retention is defined as continued participation within the trial until 4-7 months post enrollment (90 days post surgery) (T3).

  • Change in physical functionFrom enrollment (T1) to 1-4 months post enrollment (before surgery) (T2)

    Physical function will be measured by the Short Performance Physical Battery (SPPB). Change in physical function will be measured and compared between the (P)REHAB and standard of care arms. SPPB scores range from zero to 12 possible points. SPPB score of 3-9 points in persons with possible sarcopenia but no mobility disability indicates frailty; SPPB score of 10 or greater for persons with no sarcopenia and no mobility disability indicates robustness. Persons with a score of 2 or lower who have sarcopenia, potential cachexia, and mobility disability are determined to be disabled.

  • Change in physical functionFrom 1-4 months post enrollment (before surgery) (T2) to 4-7 months post enrollment (90 days post surgery) (T3)

    Physical function will be measured by the Short Performance Physical Battery (SPPB). Change in physical function will be measured and compared between the (P)REHAB and standard of care arms. SPPB scores range from zero to 12 possible points. SPPB score of 3-9 points in persons with possible sarcopenia but no mobility disability indicates frailty; SPPB score of 10 or greater for persons with no sarcopenia and no mobility disability indicates robustness. Persons with a score of 2 or lower who have sarcopenia, potential cachexia, and mobility disability are determined to be disabled.

  • Change in physical functionFrom enrollment (T1) to 4-7 months post enrollment (90 days post surgery) (T3)

    Physical function will be measured by the Short Performance Physical Battery (SPPB). Change in physical function will be measured and compared between the (P)REHAB and standard of care arms. SPPB scores range from zero to 12 possible points. SPPB score of 3-9 points in persons with possible sarcopenia but no mobility disability indicates frailty; SPPB score of 10 or greater for persons with no sarcopenia and no mobility disability indicates robustness. Persons with a score of 2 or lower who have sarcopenia, potential cachexia, and mobility disability are determined to be disabled.